Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.582
Bid: 1.57
Ask: 1.60
Change: -0.023 (-1.43%)
Spread: 0.03 (1.911%)
Open: 1.60
High: 1.60
Low: 1.56
Prev. Close: 1.608
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Challenger Energy hails Saffron-2 well; SDCL placing

Thu, 02nd Sep 2021 21:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Challenger Energy Group PLC - oil and gas producer in the Caribbean - Considers development of the Saffron-2 well to be economically justified, based on current production rates. Work is underway to update the geological and reservoir model with the results of Saffron-2. Talks with Arena Investors LP over funding continue. Challenger is investigating farm-out options and reserve based lending options. Challenger does not expect to issue further convertible loan notes under the facility that expired in July.

----------

Premier African Minerals PLC - metals and rare earths miner - Encounters visible spodumene mineralisation at the Zulu lithium and tantalum project in Zimbabwe. First assay results from the project are expected this month, and a third rig is expected in October.

----------

Good Energy Group PLC - Chippenham-based renewable energy utility - Holders of 27% of shares have accepted Ecotricity Group Ltd's 340p-per-share takeover offer, including the 25% already owned by Ecotricity. The offer remains open for acceptance.

----------

Oracle Power PLC - coal miner in Pakistan and gold explorer in Western Australia - Receives conversion notice for a further GBP100,000 of the GBP1.5 million share subscription announced in July 2020. Oracle will issue 31.3 million shares. GBP400,000 remains outstanding for conversion under the subscription.

----------

Active Energy Group PLC - London-based biomass fuel producer - Results from an independent analysis show that Active Energy's CoalSwitch pellets are superior to white pellets, producing less ash, less carbon and more heat.

----------

Sensyne Health PLC - Oxford-based healthcare software developer - Signs five-year research agreement with Great Ormond Street Hospital in London to analyse anonymised patient data using clinical artificial intelligence. The agreement focuses on paediatric drug discovery, clinical decision support tools and clinical trial design.

----------

Hemogenyx Pharmaceuticals PLC - London-based blood disease drug developer - Patent application, titled "Monocloncal Antibodies to Human FLT3/FLK2 Receptor Protein", approved in the US. The patent is another important step in develping Hemogenyx's intellectual property and protecting its drug candidates, company says.

----------

Tiziana Life Sciences PLC - London-based cancer drug developer - Signs licence deal with Precision Biosciences Inc, a Durham, North Carolina-based company developing CAR T-cell therapies. The two companies will explore whether Tiziana's foralumab can improve the outcome of CAR T-cell therapy. "Precision will be responsible for the development, commercialization, and costs for use of foralumab, and Tiziana will receive upfront payment, certain milestone payments, and royalties," Tiziana says.

----------

SDCL Energy Efficiency Income Trust PLC - investor in energy infrastructure - Plans to issue 158.4 million shares at 110.5 pence each, a 6.0% discount to the Wednesday closing price, through an open offer, placing, offer for subscription and intermediaries offer. That would raise around GBP175 million. The money will be used to invest in a pipeline of opportunities worth over GBP200 million.

----------

Zephyr Energy PLC - oil and gas explorer in the Rocky Mountain region - Test results from the State 16-2LN-CC well in the Paradox Basin, Utah, provide strong evidence of the potential to develop the Cane Creek reservoir as a hydraulically stimulated resource play. Final well completion design work is underway and the company has secured equipment and a completion crew. Production testing will start in October and initial flow test results are expected by the end of that month.

----------

Goldstone Resources Ltd - gold explorer in Ghana, Senegal and Gabon - Deadline to pay interest on a loan from Asia Investments Management Services Ltd is further extended to September 19. Interest will continue to accrue at a 17% rate. Goldstone is in talks with AIMS to reschedule and restructure the loan.

----------

SolGold PLC - gold and copper explorer in Ecuador - Exploration drilling at the Rio Amarillo project is underway. Hole 1 returned encouraging surface rock-saw channel sample results. "The regional geological setting and gross geological architecture at Rio Amarillo is very impressive," Technical Services Manager Benn Whistler says.

----------

Empyrean Energy PLC - oil and gas explorer in China, Indonesia and California - Awards integrated drilling contract for the Jade prospect offshore China to China Oilfield Services Ltd. COSL's drilling cost estimate of USD12.3 million is lower than the previous estimate for USD18.5 million. Well spud date target set for December 15 to December 30.

----------

Supply@Me Capital PLC - London-based inventory monetisation services provider - Agrees a 12-month loan facility provided by ARC Group. The facility includes an initial tranche of GBP5 million, with a further GBP2 million available within 60 days, at an interest rate of 10%. Warrants will be issued for 20% of the total value. The facility will replace the subscription agreement with Negma Group Ltd, and the remaining GBP2.1 million in convertible bonds held by Negma will be repaid in cash. Supply@Me continues to explore a Nasdaq listing.

----------

Corcel PLC - battery metals explorer in Papua New Guinea - Extends the dates by which Resource Mining Corp Ltd has to repay its debt of AUD4.8 million, around GBP2.5 million. The first AUD2.8 million is now due on October 31 instead of September 30. The remainder continues to be due on January 14. This is to allow Resource Mining time to hold its general meeting, following Corcel's acquisition of the Wo Wo Gap nickel-cobalt project from Resource Mining. As consideration for the acquisition, Corcel is "releasing all liabilities and obligations" in connection with the debt.

----------

By Ivan Edwards; ivanedwards@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
Today 12:19

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

Read more
16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases.

Read more
14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections.

Read more
9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.

Read more
2 Feb 2024 10:44

IN BRIEF: Hemogenyx hails US patent application progress

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.

Read more
16 Jan 2024 11:13

Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Tuesday said it submitted a complete response to the previously announced clinical hold of the investigational new drug application to the US Food & Drug Administration.

Read more
8 Jan 2024 10:56

Hemogenyx Pharmaceuticals completes process qualification run

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it completed a process qualification run.

Read more
28 Nov 2023 16:53

TRADING UPDATES: Upland Resources completes technical study at Sarawak

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Nov 2023 10:52

Hemogenyx shares up as says CBR platform a potential cancer treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said its chimeric based receptor platform could "potentially" be used to treat cancer and viral diseases.

Read more
15 Nov 2023 15:43

Hemogenyx Pharmaceuticals completes lentivirus re-manufacture

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said it has completed the re-manufacturing of an improved lentivirus devoid of splice variants.

Read more
28 Sep 2023 14:24

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Sep 2023 14:37

TRADING UPDATES: Avingtrans buys Adaptix, TPXimpact sells Questers

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
18 Sep 2023 13:00

Hermogenyx shares soar on new partnership with Prevail Partners

(Sharecast News) - Shares in biopharma group Hemogenyx surged on Monday after the company received a $0.83m investment from Prevail Partners as it continues to work on its planned clinical trial for leukaemia treatment.

Read more
14 Sep 2023 14:31

Hemogenyx Pharma says US FDA accepts Hemo-Car-T clinical hold lift plan

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said the US Food & Drug Administration has accepted its plan to address concerns which sparked a clinical hold on its chimeric antigen receptor T-cell or Hemo-Car-T therapy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.